Stocks
Fate Therapeutics (FATE) EBITDA US GAAP (year values) |
|||||||||
| 2021 | 2022 | 2023 | 2024 | 2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | -211.1 | -294.6 | -172.2 | -176.6 | -127.0 | -121.6 | ||
| Changes by years, y/y, % | +69% | +40% | -42% | +3% | -28% | +0.3% | |||
Fate Therapeutics. EBITDA US GAAP, bln rub
Fate Therapeutics. EBITDA US GAAP, changes, %
Fate Therapeutics. EBITDA US GAAP, sum by quarters, bln rub
Fate Therapeutics (FATE) EBITDA US GAAP (quarter values) |
||||||||
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | LTM ? | |||
| EBITDA, bln rub | ? | -37.9 | -30.8 | -29.0 | -31.7 | -30.1 | -121.6 | |
| Changes by years, y/y, % | -18% | -24% | -39% | -25% | -21% | |||
| Changes by quarters, q/q, % | -10% | -19% | -6% | +9% | -5% | |||
